ROME — There are conflicts in the literature concerning the association of Ozempic with increased risk or worsening of diabetic retinopathy.
A real-world analysis presented at the FLORetina-ICOOR meeting presented by Aleksandra Rachitskaya, MD, showed no significant difference in clinical worsening of DR between patients treated with Ozempic (semaglutide, Novo Nordisk) vs. a control group.
Ozempic is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) used in patients with diabetes type 2 to improve glycemic control. Increased rates of DR events in patients treated with Ozempic